Harrow Inc HROW
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HROW is a good fit for your portfolio.
News
-
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
-
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
-
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
-
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
-
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
-
Harrow Announces New Appointments to its Board of Directors
Trading Information
- Previous Close Price
- $10.27
- Day Range
- $9.87–10.26
- 52-Week Range
- $7.61–28.17
- Bid/Ask
- $9.98 / $10.00
- Market Cap
- $353.27 Mil
- Volume/Avg
- 267,822 / 479,729
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.57
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 217
- Website
- https://www.harrow.com
Comparables
Valuation
|
Metric
|
HROW
|
EYPT
|
EGRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 0.98 |
Price/Book Value | 5.10 | 3.03 | 0.24 |
Price/Sales | 2.57 | 13.92 | 0.23 |
Price/Cash Flow | 30.52 | — | 1.24 |
Price/Earnings
HROW
EYPT
EGRX
Financial Strength
|
Metric
|
HROW
|
EYPT
|
EGRX
|
|---|---|---|---|
Quick Ratio | 2.42 | 5.25 | 1.52 |
Current Ratio | 2.83 | 5.45 | 2.16 |
Interest Coverage | −0.11 | −61.28 | 5.39 |
Quick Ratio
HROW
EYPT
EGRX
Profitability
|
Metric
|
HROW
|
EYPT
|
EGRX
|
|---|---|---|---|
Return on Assets (Normalized) | −3.03% | −29.34% | 6.32% |
Return on Equity (Normalized) | −16.62% | −54.05% | 10.51% |
Return on Invested Capital (Normalized) | 4.51% | −48.97% | 9.73% |
Return on Assets
HROW
EYPT
EGRX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Spkqcllpw | Zjqxvlz | $70.9 Bil | |
ZTS
| Zoetis Inc Class A | Gdnsvlzc | Myfmt | $68.9 Bil | |
HLN
| Haleon PLC ADR | Lwkfxxkb | Wbyzr | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Lmptfvd | Pjzp | $14.7 Bil | |
VTRS
| Viatris Inc | Wvltjysd | Gwmf | $13.7 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Cfmjwstr | Flkc | $11.9 Bil | |
CTLT
| Catalent Inc | Lzmhypcm | Yffpts | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Pxggwwks | Yzjbq | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Mvlrzgq | Fsnbn | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Cvgtqpjx | Wnrtgl | $3.5 Bil |